Your Journey to Treat Demodex Blepharitis (DB) Starts Now






Understanding Demodex Blepharitis

Demodex blepharitis (DB) is an eyelid disease caused by an infestation of *Demodex* mites, a common mite found on humans.^{1,2}

- It's estimated that approximately 25 million eye care patients in the US are affected by DB.^{3,4}
- Patients with DB may experience eyelid redness, itchiness, swelling, inflammation, and crusties (collarettes) on the eyelashes.^{1,3,5}
- When left untreated, DB can leave you more prone to other eye-related diseases.¹



Close up of mites on eyelash.*

Eyelashes with mites.†

Crusties (collarettes)



Real patient with DB used XDEMVY twice daily, in each eye, for 6 weeks. Results may vary.

XDEMVY° Is the Game-Changer in Your Fight Against DB

As the first and only FDA-approved prescription eye drop treatment for *Demodex* blepharitis, XDEMVY can target and kill the mites, get rid of eyelid redness, and reduce crusties (collarettes).⁶

Treatment Is Made Simple With XDEMVY

- XDEMVY treatment is 1 drop per eye, twice a day, ~12 hours apart, for just 6 weeks. It is important to take XDEMVY for the entire 6 weeks.
- If you're using other topical eye medications, ensure a gap of at least 5 minutes between each.
- Remove contact lenses and wait 15 minutes after applying XDEMVY before reinserting.
- Consult with your doctor about continuing your eyelid hygiene routine.

Indications and Usage

XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

Important Safety Information

Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Please see additional Important Safety Information throughout.

Supporting Your XDEMVY® Prescription Experience

Navigating XDEMVY Access and Savings

If XDEMVY is prescribed to you, your doctor will send your prescription to a nationwide pharmacy.

1 Expect a text or phone call directly from the pharmacy and have your prescription drug insurance information handy.

It is important that you answer so your treatment is not delayed.

- If you don't receive a call or text within 48 hours, reach out to the selected pharmacy.
- 2 The pharmacy will complete any insurance requirements with your doctor.
- If a copay is needed per your insurance coverage, the pharmacy will require payment. Ask your pharmacy about additional affordability programs that might be available.
- 4 The pharmacy will work with you to arrange delivery to your home or local pharmacy.

For XDEMVY access support, contact Tarsus Connect at 1-866-846-3092.





With XDEMVY, you can take control and address the root cause of your Demodex blepharitis.⁶



Text "mites" to XDEMVY (933689) to chat or visit XDEMVY.com to dive deeper.

Important Safety Information (Continued)

Handling the Container: Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

When to Seek Physician Advice: Immediately seek a physician's advice concerning the continued use of XDEMVY if you develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions.

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals at 1-888-421-4002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information attached.

By prescription only.

References: 1. Fromstein S, Harthan J, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optom (Auckl). 2018;10:57-63. 2. Rhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311-318. 3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Opthalmol. 2022;16:1153-1164. 4. O'Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of Demodex blepharitis. Clin Opthalmol. 2022;16:2979-2987. 5. Sędzikowska A, Osęka M, Grytner-Zięcina B. Ocular symptoms reported by patients infested with Demodex mites. Acta Parasitol. 2016;61(4):808-814. 6. XDEMVY. Prescribing Information. Tarsus Pharmaceuticals Inc: 2023.

*Image Credit: Laura Periman, MD † Image Credit: Vin Dang, OD

